TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01472276

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based program
Description: Provided with the web-based program
Study: NCT00156663

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Caring for Women Veterans
Study: NCT01337401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: 30mg once daily, oral until disease progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30mg, once daily, oral until 24 weeks or disease progression if sooner
Study: NCT01552343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Desmopressin orally disintegrating tablets. Female participants took a 25 μg tablet and male participants took a 75 μg tablet one hour prior to bedtime for one month.
Study: NCT03811015

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT01866670

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: relaxation therapy
Description: Relaxation Therapy: deep breathing
Study: NCT03811015

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Receive FDG

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fludeoxyglucose F-18
Description: Receive FDG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Receive FDG

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo observation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT03420833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy pacemaker (CRT-P)
Description: A pacemaker is an implantable, battery-powered minicomputer that sends electrical pulses to the heart whenever it detects a slow heartbeat or no heartbeat at all. When it senses a slow heartbeat or lack of heartbeat, it sends electrical impulses to restore a normal rhythm. Cardiac resynchronization therapy pacemakers, or CRT-Ps, treat heart failure by resynchronizing electrical impulses in the heart's four chambers, improving the heart's ability to pump blood to the body effectively and efficiently.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy pacemaker (CRT-P)
Description: A pacemaker is an implantable, battery-powered minicomputer that sends electrical pulses to the heart whenever it detects a slow heartbeat or no heartbeat at all. When it senses a slow heartbeat or lack of heartbeat, it sends electrical impulses to restore a normal rhythm. Cardiac resynchronization therapy pacemakers, or CRT-Ps, treat heart failure by resynchronizing electrical impulses in the heart's four chambers, improving the heart's ability to pump blood to the body effectively and efficiently.
Study: NCT03332017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Oral administration as a capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Intravenous administration
Study: NCT01261312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Subcutaneous injection
Study: NCT01552343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Desmopressin orally disintegrating tablets. Female participants took a 25 μg tablet and male participants took a 75 μg tablet one hour prior to bedtime for one month.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match the 25 μg tablet of active drug taken by female participants or the 75 μg tablet taken by males. One placebo tablet taken one hour prior to bedtime for one month.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match the 25 μg tablet of active drug taken by female participants or the 75 μg tablet taken by males. One placebo tablet taken one hour prior to bedtime for one month.
Study: NCT02219230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active knee (Ossur Power Knee II)
Description: Prosthetic knee with active control system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive knee (Ossur Rheo)
Description: Prosthetic knee with adaptive control system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive knee (Various manufacturers)
Description: Prosthetic knee with mechanical control system.
Study: NCT00189826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: immunosuppression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: immunosuppression
Study: NCT00784758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fenzian Device
Description: Three 20-minute treatments with the Fenzian Device per week for 5 weeks (for a total of 15 treatments)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Three 20-minute treatments with the sham device per week for 5 weeks (for a total of 15 treatments) (NOTE: This arm is similar to a placebo arm in a drug trial.)
Study: NCT03677570

Intervention type: DIAGNOSTIC_TEST
Intervention: postural stability
Description: Postural Stability, vertical jump test, hexagonal obstacle test, trunk flexion test, trunk extension test, side bridge test,prone bridge test

Intervention type: DIAGNOSTIC_TEST
Intervention: postural stability
Description: Postural Stability, vertical jump test, hexagonal obstacle test, trunk flexion test, trunk extension test, side bridge test,prone bridge test
Study: NCT01149733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Test 0.4 mg Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Reference Listed 0.4 Capsule
Study: NCT00545506

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional bandage

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: warming bandage
Study: NCT01434953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Labeled prehypertension
Description: A study physician informs subjects of their blood pressure level. Subjects are told they have prehypertension and are informed of the associated health risks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unlabeled prehypertension
Description: A study physician informs subjects of their blood pressure level. The term prehypertension is not used and associated health risks are not discussed.
Study: NCT01449383

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low meat high fibre
Description: less than 30g red meat and at least 40g dietary fibre per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: high meat low fibre
Description: at least 200g red meat (pork, beef or other mammals) and not more than 20g dietary fibre per day
Study: NCT05806853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA
Description: Glu-NH-CO-NH-Lys-(Ahx)-\[68Ga(HBED-CC)\] (68Ga-PSMA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-RM2
Description: Bombesin receptor antagonist (68Ga-RM2)
Study: NCT02347293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High levels of indigestible carbohydrates
Study: NCT03723070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Cryterion Cardiac Cryoablation System
Description: Cryoablation System that includes a Balloon Catheter, Circular Mapping Catheter, Steerable Sheath and Cryoablation Console. In combination, components of the System will be inserted into the left atrium and a thermal injury at the PV ostium will be created to electrically isolate the veins
Study: NCT02113215

Intervention type: PROCEDURE
Intervention: Stable Isotope Infusion
Description: 9-hour infusion of stable isotope tracers

Intervention type: PROCEDURE
Intervention: Stable Isotope Infusion
Description: 9-hour infusion of stable isotope tracers

Intervention type: PROCEDURE
Intervention: Stable Isotope Infusion
Description: 9-hour infusion of stable isotope tracers

Intervention type: PROCEDURE
Intervention: Stable Isotope Infusion
Description: 9-hour infusion of stable isotope tracers
Study: NCT03546543

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Position change
Description: Each subject will serve as his or her own control. Half of the infants will be placed supine for 3 hours, followed by 3 hours of prone positioning and back to supine for 3 hours and the other half will be start in prone position with consecutive periods of supine and then prone

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Position change
Description: Each subject will serve as his or her own control. Half of the infants will be placed supine for 3 hours, followed by 3 hours of prone positioning and back to supine for 3 hours and the other half will be start in prone position with consecutive periods of supine and then prone
Study: NCT03672825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REcycled CartiLage Auto/Allo IMplantation
Description: Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs).
Study: NCT01942512

Intervention type: DEVICE
Intervention: Endovascular treatment of intracranial aneurysm
Study: NCT02347293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low levels of indigestible carbohydrates
Study: NCT02687737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electromyography
Description: During the fine wire electromyography (EMG), the participant will be asked to complete breathing exercises at 50% and 75% of their maximum capacity (determined prior to fine wire EMG using manometry) to determine activation and recruitment of genioglossus muscle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maximum expiratory pressure
Description: The participants' maximum expiratory pressure (MEP) will be assessed using a hand-held digital manometer (MP01, Micro Direct Inc.). The subject will be standing and while wearing a nose clip be asked to blow out as hard and fast as they can to determine their MEP. This will be completed a maximum of three times to obtain values within close range of one another.
Study: NCT01261312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Subcutaneous injection
Study: NCT02687737

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Videofluoroscopy
Description: Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swallowing Tasks
Description: These include: an anterior tongue press to the alveolar ridge (behind the front molars), a saliva swallow, a 10 mL barium swallow, a 10 mL barium hard swallow (i.e. swallowing with extra effort), and two breathing exercise trials at 50% MEP and 75% MEP.
Study: NCT00730093

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: B12 vitamin (Cyanocobalamin)
Description: Arm A: B12 vitamin (Cyanocobalamin)
Study: NCT03819699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF20513
Description: Lu AF20513 suspension for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF20513
Description: Lu AF20513 suspension for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF20513
Description: Lu AF20513 suspension for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: booster vaccine
Description: booster vaccine (Cohort 2) - to be administered as per national recommendations
Study: NCT01675700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin patch
Description: Nitroglycerin 0.1 mg/hr patch
Study: NCT04439409

Intervention type: DEVICE
Intervention: Holter electrocardiogram
Description: Holter electrocardiogram will be carried during 7 days to measure heart's electrical activity continuously.
Study: NCT04230239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: CPX-351 has IV administration Vyxeos contains 2.2 mg/mL and 5 mg/mL powder for concentrate for solution for infusion of Daunorubicin and cytarabine.~Each vial contains 44 mg of daunorubicin and 100 mg of cytarabine. After reconstitution, the solution contains 2.2 mg/mL daunorubicin and 5 mg/mL cytarabine
Study: NCT01435915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole
Description: Ropinirole 2 milligrams once daily prolonged release tablet will be given at 24-hour intervals in the morning.~Single and repeat dose treatment periods will be separated by 7 days of washout period.
Study: NCT00126737

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight Control Nutritional Program
Description: a week of food diary and information about dietary fat intake and proper proportions of vegetables.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight Control Nutritional Program
Description: a week of food diary and information about dietary fat intake and proper proportions of vegetables.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based exercise program
Description: 24 week home-based exercise program encompassed aerobic exercises, isometric and isotonic exercises, and stretching exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based exercise program
Description: 24 week home-based exercise program encompassed aerobic exercises, isometric and isotonic exercises, and stretching exercises.
Study: NCT03834116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: A pressure threshold device will be used to deliver IMT, which is commercially available by Phillips Respironics.
Study: NCT01692015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire on dietary history

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire on dietary history

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire on nosebleed severity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire on nosebleed severity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One week food diary generated by weighing foods

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood tests for full blood count, albumin, and indices of nutritional status
Study: NCT04095013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine, fentanyl
Description: Group A: hyperbaric Bupivacaine 10mg with fentanyl 10micrograms,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine, dexmedetomidine
Description: Group B: hyperbaric Bupivacaine 10 mg with dexmedetomidine5 micrograms
Study: NCT01388426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7eye( Panoptx)™ moisture chamber glasses
Description: moisture chamber glasses
Study: NCT00675480

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Description: Aspiration Thrombectomy prior to stent implantation in patients with ST segment elevation myocardial infarction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary angioplasty
Description: Standard primary angioplasty with stent implantation
Study: NCT04136678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking training
Description: 15 minutes of conventional walking training 15 minutes of treadmill backward walking training 15 minutes of treadmil forward walking training
Study: NCT01177176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extended Care Management
Description: Telephone-based care management of tobacco cessation for 3 months after hospital discharge that features 2 innovations: (1) to increase medication use, smokers receive a free refillable 30-day sample of their choice of FDA-approved smoking cessation medication (nicotine replacement, bupropion, or varenicline) at hospital discharge; (2) to increase counseling cost-effectiveness, interactive voice recognition (IVR) technology is used to make automated telephone calls to identify the smokers seeking or most likely to benefit from continued counseling after hospital discharge.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Usual care provided to hospitalized smokers during their inpatient stay, with no post-discharge care management plan
Study: NCT02886663

Intervention type: OTHER
Group type: OTHER
Intervention: stimulation of the blind visual field

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stimulation of the blind visual field
Study: NCT04410822

Intervention type: OTHER
Intervention: Clinical tests
Description: Semi-qualitative interviews and questionnaire FITAS
Study: NCT04462679

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMMIT mHealth application
Description: We will develop Community-based mHealth Motivational Interviewing Tool (COMMIT) using iterative design and testing with frequent, structured input from the key stakeholders: community health workers (CHWs), their supervisors and youth living with HIV (YLWH).The tool will be used by community CHWs in Achham, Nepal to: 1) obtain decision-support to deliver motivational interviewing (MI) for patients in their communities, and 2) capture consented audio recordings of client interactions for review and feedback by their supervisors, allowing CHWs to maintain MI skills beyond the initial training period.
Study: NCT03126149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06667272
Description: Single ascending dose of PF-06667272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06667272
Description: Single ascending dose of PF-06667272
Study: NCT01982630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521
Study: NCT03126149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06667272
Description: Single ascending dose of PF-06667272
Study: NCT01982630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02844361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplantation
Description: Patients in this group will receive BEAC(BCNU+VP-16+CTX+Ara-c) as conditioning regimen and then with autologous stem cells feedback

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional chemotherapy
Description: Patients in this group will receive previously effective chemotherapeutic regimen as consolidation therapy
Study: NCT04644900

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chewed mint gum
Description: In the preoperative waiting area before transferring to the operating room,patients in group G chewed mint gum for 2 minutes and then spit it out.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwash
Description: Patients in the mouthwash group took 15 ml honeysuckle antibacterial mouthwash in their mouths, and vomited them out after 2 minutes
Study: NCT01245244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine oral mixture

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: orange juice
Description: orange juice
Study: NCT01650805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ponatinib
Description: 45 mg tablet, taken orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib (Gleevec/ Glivec)
Description: 400 mg tablet, taken orally once daily